Skip to main content

Advertisement

Table 3 Adverse events (VCOG-CTCAE)

From: Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer

  Grade sDox sDox + I2 mDox mDox + I2
Vomiting 1 1 (25%) 1 (17%) 1 (17%) 2 (18%)
2 1 (25%) 1(17%) 1 (17%)  
3     
4     
Diarrhea 1 1 (25%) 1 (17%) 1 (17%) 2 (18%)
2 1 (25%) 1 (17%) 1 (17%) 1 (9%)
3     
4     
Anorexia 1 2 (50%) 1 (17%) 1 (17%) 1 (9%)
2 1 (25%) 1 (17%)   
3     
4     
Lethargy 1 1 (25%) 1 (17%) 1 (17%) 1 (9%)
2 1 (25%) 1 (17%) 1 (17%) 1 (9%)
3     
4     
Anemiaa 1 2 (50%) 2 (33%) 2 (33%) 3 (27%)
2     
3     
4     
Neutropenia 1 1(25%) 1 (17%) 1 (17%) 1 (9%)
2     
3     
4     
  1. aAnemia includes: hematocrit, hemoglobin and erythrocyte values (mean globular volume and mean hemoglobin concentration)